NASDAQ:CBDC Apotheca Biosciences (CBDC) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free CBDC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.0002▼$0.000250-Day Range$0.00▼$0.0852-Week Range$0.00▼$0.31VolumeN/AAverage Volume21,204 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Apotheca Biosciences alerts: Email Address Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. About Apotheca Biosciences Stock (NASDAQ:CBDC)Apotheca Biosciences, Inc. develops cutting-edge medical products, nutraceuticals, formulations, and delivery technologies for the healthcare and consumer care industry in the United States. The company's products include transdermal, sublingual, and nasal delivery devices for dosing of cannabinoids. It also provides CBD pain cream, gel capsules, patches, and sleep tablets; and Promed, anti-aging and cosmetic products. The company was incorporated in 2014 and is based in Saint Petersburg, Florida.Read More Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. CBDC Stock News HeadlinesJuly 4, 2023 | finance.yahoo.comThe Digital Dollar Project Publishes a Risk Framework for Consideration of a U.S. CBDCApril 16, 2023 | finance.yahoo.comThe Digital Currency Monetary Authority (DCMA) Launches an International Central Bank Digital Currency (CBDC)April 29, 2024 | Unstoppable Prosperity (Ad)Charles Payne’s Gift to Stock InvestorsRight now, millions of good honest folks are feeling the squeeze. Last year's terrible market did a number on their accounts. Stock values plunged. Retirement accounts lost too.March 24, 2023 | markets.businessinsider.comFlorida Governor Ron DeSantis proposes banning a digital currency from the Fed, arguing it will stifle innovation and promote surveillanceFebruary 27, 2023 | finance.yahoo.comWe're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash WiselyFebruary 19, 2023 | 247wallst.comJapan Joins the CBDC Race, Will Conduct Tests in AprilJanuary 27, 2023 | 247wallst.comHM Treasury Seeking Head of CBDC as UK Moves Closer to the Digital PoundJanuary 23, 2023 | finance.yahoo.comThe Digital Dollar Project Publishes Updated White Paper Furthering Exploration of a U.S. CBDCApril 29, 2024 | Unstoppable Prosperity (Ad)Charles Payne’s Gift to Stock InvestorsRight now, millions of good honest folks are feeling the squeeze. Last year's terrible market did a number on their accounts. Stock values plunged. Retirement accounts lost too.October 14, 2022 | investing.comThe Reserve Bank of India States Features of CBDC in Concept NoteSeptember 27, 2022 | seekingalpha.comEVFM Evofem Biosciences, Inc.June 16, 2022 | msn.comApotheca celebrates Healthy Dad's DaySee More Headlines Receive CBDC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apotheca Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:CBDC CUSIPN/A CIK1632053 Webwww.apothecabiosciences.com Phone727-228-3994FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Craig HuffmanLegal CouncilMs. Karin RohretSec.Key Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors CBDC Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Apotheca Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apotheca Biosciences investors own include Cross Timbers Royalty Trust (CRT), Hemp (HEMP), Arbor Realty Trust (ABR), InfraCap MLP ETF (AMZA), Alliance Resource Partners (ARLP), BP Prudhoe Bay Royalty Trust (BPT), Refined Metals (CADMF) and This page (NASDAQ:CBDC) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press4 coins to be the “Next Bitcoin”True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apotheca Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.